Table 1.
Baseline demographic and clinical characteristics.*
| Participants enrolled | N=17 |
|---|---|
|
| |
| Male sex | 88% (15) |
|
| |
| Race | |
| African American | 24% (4) |
| Hispanic | 41% (7) |
| White | 35% (6) |
|
| |
| Age (years) | 60 (54, 63) |
|
| |
| Body mass index (kg/m2) | 27 (27, 30) |
|
| |
| Current tobacco use | 18% (3) |
|
| |
| Blood Pressure (mmHg) | |
| Systolic | 130 (122, 138) |
| Diastolic | 72 (66, 83) |
|
| |
| Framingham risk score (%) | 10 (7, 12) |
|
| |
| CD4+ T lymphocyte count (cells/mm3) | 625 (413, 729) |
|
| |
| PI | 71% (12) |
| Atazanavir/ritonavir | 18% (3) |
| Atazanavir | 18% (3) |
| Darunavir/ritonavir | 18% (3) |
| Fosamprenavir/ritonavir | 6% (1) |
| Lopinavir/ritonavir | 12% (2) |
| NNRTI | 29% (5) |
| Efavirenz | 24% (4) |
| Nevirapine | 6% (1) |
| NRTI | 94% (16) |
| Abacavir | 29% (5) |
| Emtricitabine | 59% (10) |
| Lamivudine | 29% (5) |
| Tenofovir | 65% (11) |
| Zidovudine | 6% (1) |
| Integrase inhibitor (raltegravir) | 29% (5) |
| Entry inhibitor (maraviroc) | 6% (1) |
|
| |
| Glucose (mg/dL) | 96 (92, 105) |
|
| |
| Total cholesterol (mg/dL) | 166 (145,194) |
| Triglycerides (mg/dL) | 107 (79, 145) |
| LDL cholesterol (mg/dL) | 97 (70, 111) |
| HDL cholesterol (mg/dL) | 44 (39, 52) |
|
| |
| Diabetesa | 12% (2) |
|
| |
| Hypertensiona | 65% (11) |
|
| |
| Hyperlipidemiaa | 82% (14) |
*
Values are expressed as median (interquartile range) or percent (n).
a
Defined as self-reported diagnosis or on-therapy at baseline.
PI: protease inhibitor, NNRTI: non nucleoside reverse transcriptase inhibitor, NRTI: nucleoside reverse transcriptase inhibitor, LDL: low-density lipoprotein, HDL: high-density lipoprotein